Cargando…

Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo

Triptolide (TP) displays a strong immunosuppression function in immune-mediated diseases, especially in the treatment of rheumatoid arthritis. However, in addition to its medical and health-related functions, TP also exhibits diverse pharmacological side effects, for instance, liver and kidney toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li, Wang, Tengteng, Li, Qiang, Huang, Jing, Xu, Hao, Li, Jinlong, Wang, Yongjun, Liang, Qianqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907735/
https://www.ncbi.nlm.nih.gov/pubmed/27354796
http://dx.doi.org/10.2147/IJN.S104593
_version_ 1782437589118091264
author Zhang, Li
Wang, Tengteng
Li, Qiang
Huang, Jing
Xu, Hao
Li, Jinlong
Wang, Yongjun
Liang, Qianqian
author_facet Zhang, Li
Wang, Tengteng
Li, Qiang
Huang, Jing
Xu, Hao
Li, Jinlong
Wang, Yongjun
Liang, Qianqian
author_sort Zhang, Li
collection PubMed
description Triptolide (TP) displays a strong immunosuppression function in immune-mediated diseases, especially in the treatment of rheumatoid arthritis. However, in addition to its medical and health-related functions, TP also exhibits diverse pharmacological side effects, for instance, liver and kidney toxicity and myelosuppression. In order to reduce the side effects, a nano drug carrier system (γ-PGA-l-PAE-TP [PPT]), in which TP was loaded by a poly-γ-glutamic acid-grafted l-phenylalanine ethylester copolymer, was developed. PPT was characterized by photon scattering correlation spectroscopy and transmission electron microscopy, which demonstrated that the average diameter of the drug carrier system is 98±15 nm, the polydispersity index is 0.18, the zeta potential is −35 mV, and the TP encapsulation efficiency is 48.6% with a controlled release manner. The methylthiazolyldiphenyl-tetrazolium bromide assay and flow cytometry revealed that PPT could decrease toxicity and apoptosis induced by free TP on RAW264.7 cells, respectively. The detection of reactive oxygen species showed that PPT could decrease the cellular reactive oxygen species induced by TP. Compared with the free TP-treated group, PPT improved the survival rate of the mice (P<0.01) and had no side effects or toxic effects on the thymus index (P>0.05) and spleen index (P>0.05). The blood biochemical indexes revealed that PPT did not cause much damage to the kidney (blood urea nitrogen and creatinine), liver (serum alanine aminotransferase and aspartate aminotransferase), or blood cells (P>0.05). Meanwhile, hematoxylin and eosin staining and terminal-deoxynucleotidyl transferase dUTP nick-end labeling staining indicated that PPT reduced the damage of free TP on the liver, kidney, and spleen. Our results demonstrated that PPT reduced free TP toxicity in vitro and in vivo and that it is a promising fundamental drug delivery system for rheumatoid arthritis treatment.
format Online
Article
Text
id pubmed-4907735
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49077352016-06-28 Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo Zhang, Li Wang, Tengteng Li, Qiang Huang, Jing Xu, Hao Li, Jinlong Wang, Yongjun Liang, Qianqian Int J Nanomedicine Original Research Triptolide (TP) displays a strong immunosuppression function in immune-mediated diseases, especially in the treatment of rheumatoid arthritis. However, in addition to its medical and health-related functions, TP also exhibits diverse pharmacological side effects, for instance, liver and kidney toxicity and myelosuppression. In order to reduce the side effects, a nano drug carrier system (γ-PGA-l-PAE-TP [PPT]), in which TP was loaded by a poly-γ-glutamic acid-grafted l-phenylalanine ethylester copolymer, was developed. PPT was characterized by photon scattering correlation spectroscopy and transmission electron microscopy, which demonstrated that the average diameter of the drug carrier system is 98±15 nm, the polydispersity index is 0.18, the zeta potential is −35 mV, and the TP encapsulation efficiency is 48.6% with a controlled release manner. The methylthiazolyldiphenyl-tetrazolium bromide assay and flow cytometry revealed that PPT could decrease toxicity and apoptosis induced by free TP on RAW264.7 cells, respectively. The detection of reactive oxygen species showed that PPT could decrease the cellular reactive oxygen species induced by TP. Compared with the free TP-treated group, PPT improved the survival rate of the mice (P<0.01) and had no side effects or toxic effects on the thymus index (P>0.05) and spleen index (P>0.05). The blood biochemical indexes revealed that PPT did not cause much damage to the kidney (blood urea nitrogen and creatinine), liver (serum alanine aminotransferase and aspartate aminotransferase), or blood cells (P>0.05). Meanwhile, hematoxylin and eosin staining and terminal-deoxynucleotidyl transferase dUTP nick-end labeling staining indicated that PPT reduced the damage of free TP on the liver, kidney, and spleen. Our results demonstrated that PPT reduced free TP toxicity in vitro and in vivo and that it is a promising fundamental drug delivery system for rheumatoid arthritis treatment. Dove Medical Press 2016-06-08 /pmc/articles/PMC4907735/ /pubmed/27354796 http://dx.doi.org/10.2147/IJN.S104593 Text en © 2016 Zhang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhang, Li
Wang, Tengteng
Li, Qiang
Huang, Jing
Xu, Hao
Li, Jinlong
Wang, Yongjun
Liang, Qianqian
Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title_full Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title_fullStr Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title_full_unstemmed Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title_short Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
title_sort fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907735/
https://www.ncbi.nlm.nih.gov/pubmed/27354796
http://dx.doi.org/10.2147/IJN.S104593
work_keys_str_mv AT zhangli fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT wangtengteng fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT liqiang fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT huangjing fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT xuhao fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT lijinlong fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT wangyongjun fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo
AT liangqianqian fabricationofnovelvesiclesoftriptolideforantirheumatoidactivitywithreducedtoxicityinvitroandinvivo